Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)

26 August 2023 (14:00 - 14:10)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Efthymios Ziogos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

4 More presentations in this session

Presentation thumbnail

Synergistic effect of Interleukin-1beta and cholesterol efflux capacity on outcomes in acute myocardial infarction patients

Doctor C. Materne (Paris, FR)

Abstract Slides Video

Presentation thumbnail

Analysis of immune infiltration and cuproptosis-related genes in acute myocardial infarction

Doctor Y. Xiao (Changsha, CN)

Abstract Slides Video

Presentation thumbnail

Impact of nutritional status and systemic immune-inflammation index on mortality in patients with acute myocardial infarction

Doctor H. Kwak (Daegu, KR)

Abstract Slides Video

Presentation thumbnail

Inflammatory biomarkers and long-term outcome in young stable patients 3 months after a first myocardial infarction

Doctor S. Cederstrom (Stockholm, SE)

Abstract Slides Video

Access the full session

Session thumbnail

Markers of inflammation and outcomes in patients with acute coronary syndromes

The Event

Event poster

ESC Congress 2023

26 August 2023 14:00 CET

You may be interested in

Congress Session

Ischaemia and inflammation: the role of cardiac PET in diagnosis and prognosis

Congress Session

Markers of inflammation and outcomes in patients with acute coronary syndromes

Congress Presentation

Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: together with anti-inflammatory therapy from Day 1

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources